Skip to content
  • What We Do
    • Financial Statements
    • Disclosures
    • Privacy
    • Terms Of Use
    • Multi-Asset Clearing 
    • Technology
    • Investment Banking & Capital Markets
    • Equity Research
    • Prime Brokerage
    • Wealth Management
    • Investment Management
    • List Item #1
    • List Item #2
    • List Item #3
    • List Item
    • List Item
  • Solution Guide
  • Company
    • Financial Statements
    • Disclosures
    • Privacy
    • Terms Of Use
    • About Us
    • A Look Back
    • Leadership
    • Career Opportunities
    • Community
    • Affiliates
  • Insights
  • What We Do
    • Financial Statements
    • Disclosures
    • Privacy
    • Terms Of Use
    • Multi-Asset Clearing 
    • Technology
    • Investment Banking & Capital Markets
    • Equity Research
    • Prime Brokerage
    • Wealth Management
    • Investment Management
    • List Item #1
    • List Item #2
    • List Item #3
    • List Item
    • List Item
  • Solution Guide
  • Company
    • Financial Statements
    • Disclosures
    • Privacy
    • Terms Of Use
    • About Us
    • A Look Back
    • Leadership
    • Career Opportunities
    • Community
    • Affiliates
  • Insights
Contact Us
Login
What We Do
  • Multi-Asset Clearing
  • Technology
  • Equity Research
  • Prime Brokerage
  • Wealth Management
  • Investment Management
Solution Guide
Company
  • About Us
  • A Look Back
  • Ed’s Edicts
  • Leadership
  • Career Opportunities
  • Community
  • Financial Statements
  • Find a Financial Professional
Insights
Search
Contact Us

Day: September 4, 2019

David Nierengarten: Stocks like Y-mAbs Therapeutics Which Have Advanced Assets as Well as Upside Potential

For more on David Nierengarten’s: Wedbush: Y-mAbs Could Attract Investor Attention As Market Volatility Grows

David Nierengarten: Y-mAbs Therapeutics Should be Particularly Attractive for Investors.

For more on David Nierengarten’s comments: Wedbush: Y-mAbs Could Attract Investor Attention As Market Volatility Grows

Robert Driscoll: Cidara’s Partnership with Mundipharma is a Significant Positive

For more on Robert Driscoll’s comments: Wedbush Recommends Buying Cidara Shares After Rezafungin Deal

Robert Driscoll: We See Substantial Synergies Between Both Cidara and Mundipharma Given Mundipharma Already has a Significant Global Commercial Reach with Annual Sales Over €2B

For more on Robert Driscoll’s comments: Wedbush Recommends Buying Cidara Shares After Rezafungin Deal

Technology Sector Investors in a Defensive Mode

Michael Pachter: Few Near-Term Catalysts Ahead of the Nov. 15 Launch of EA’s Star Wars Jedi: Fallen Order

For more on Michael Pachter’s comments: Activision Upgraded As Video Game Publisher Improves Key Franchises 

Upcoming iPhone Models Could Boost Apple Stock Regardless of Trade Tariffs

   

Michael Pachter: They are Hopeful That A Lot of People in the Chain of Decision-Making is Thinking About Life After the DOD and Life In the Private Sector.

For more on Michael Pachter’s comments: Amazon hiring for cloud services, Alexa products at HQ2 in Arlington, Va.

Daniel Ives: There Has Been an Accelerations of Large Enterprise Cloud Deals During the Second Quarter in the U.S. and Europe and That Microsoft is Poised to Win Many of Them

For more on Daniel Ives’ comments: Here’s A Reason To Own Microsoft’s Stock: Its Red-Hot Cloud Computing Business

Michael Pachter: Few Near-term Catalysts Ahead of Nov. 15 Launch of “Star Wars Jedi: Fallen Order

For  more on Michael Pachter’s comments: Activision Upgraded As Video Game Publisher Improves Key Franchises

Next →

Find a Financial Professional

Get the support you need to plan your financial future.
Find Now
  • What We Do
  • Solution Guide
  • Company
  • Insights
  • Contact Us
  • Financial Statements
  • Wedbush & Co.
  • Disclosures
  • Privacy
  • Terms Of Use
  • Member NYSE / FINRA / SIPC
  • Broker Check
  • 225 S. Lake Ave., Penthouse, Pasadena | CA | 91101
  • 213.688.8000